Skip to main content

Table 2 Ordinal logistic regression model building

From: Transferrin predicts trimethylamine-N-oxide levels and is a potential biomarker of cardiovascular disease

  Model 1 (Univariate) Model 2 (Multivariable with demographics) Model 3 (Finalized model)
OR (95% CI) P >|z| OR (95% CI) P >|z| OR (95%) CI) P >|z|
Age 0.98 (0.89, 1.07) 0.575 0.95 (0.85, 1.05) 0.282
Gender 0.87 (0.46, 1.66) 0.674 1.10 (0.85, 1.05) 0.824
Race white versus non-white 1.29 (0.59, 2.81) 0.524 2.92 (1.02, 8.30) 0.045
Weight (lbs) 1.01 (1.00, 1.01) 0.06 1.01 (1.00, 1.01) 0.058 1.01 (0.99, 1.03) 0.251
Waist circumference 1.05 (1.00, 1.10) 0.073 1.05 (0.99, 1.10) 0.088 0.95 (0.81, 1.10) 0.491
Transferrin Q2 versus Q1 0.32 (0.13, 0.79) 0.013 0.29 (0.12, 0.72) 0.008 0.16 (0.05, 0.52) 0.002
Transferrin Q3 versus Q1 0.66 (0.28, 1.58) 0.352 0.61 (0.24, 1.51) 0.280 0.31 (0.79, 1.20) 0.090
Transferrin Q4 versus Q1 0.55 (0.23, 1.36) 0.197 0.53 (0.21, 1.30) 0.166 0.20 (0.04, 0.95) 0.043
HDL-C Q2 versus Q1 2.66 (1.07, 6.62) 0.035 3.06 (1.19, 7.85) 0.020 2.68 (0.86, 8.32) 0.088
HDL-C Q3 versus Q1 1.10 (0.46, 2.62) 0.840 1.26 (0.50, 3.19) 0.623 1.27 (0.39, 4.12) 0.687
HDL-C Q4 versus Q1 0.66 (0.27, 1.30) 0.365 0.72 (0.27, 1.85) 0.489 1.13 (0.27, 4.79) 0.868
Triglycerides Q2 versus Q1 2.02 (0.83, 4.90) 0.122 1.99 (0.81, 4.86) 0.131 2.00 (0.62, 6.48) 0.248
Triglycerides Q3 versus Q1 1.42 (0.56, 3.61) 0.464 1.40 (0.54, 3.60) 0.488 1.12 (0.31, 4.14) 0.861
Triglycerides Q4 versus Q1 2.20 (0.93, 5.25) 0.074 2.14 (0.88, 5.20) 0.091 1.68 (0.44, 6.35) 0.446
Iron Q2 versus Q1 0.44 (0.18, 1.09) 0.077 0.50 (0.19, 1.16) 0.103 1.43 (0.39, 5.25) 0.589
Iron Q3 versus Q1 0.28 (0.11, 0.68) 0.005 0.24 (0.10, 0.62) 0.003 0.55 (0.09, 3.33) 0.515
Iron Q4 versus Q1 0.63 (0.24, 1.64) 0.345 0.56 (0.21, 1.50) 0.249 2.80 (0.28, 28.26) 0.382
Saturation Q2 versus Q1 0.57 (0.24, 1.36) 0.205 0.59 (0.25, 1.42) 0.240 0.88 (0.23, 3.30) 0.845
Saturation Q3 versus Q1 0.40 (0.17, 0.96) 0.041 0.38 (0.16, 0.93) 0.033 0.44 (0.08, 2.58) 0.365
Saturation Q4 versus Q1 0.75 (0.29, 1.91) 0.543 0.68 (0.26, 1.81) 0.442 0.31 (0.03, 3.35) 0.336
Total cholesterol Q2 versus Q1 0.34 (0.13, 0.86) 0.024 0.34 (0.13, 0.87) 0.024 0.65 (0.21, 1.97) 0.444
Total cholesterol Q3 versus Q1 0.84 (0.32, 2.23) 0.726 0.84 (0.32, 2.23) 0.726 1.66 (0.52, 5.34) 0.397
Total cholesterol Q4 versus Q1 0.50 (0.20, 1.24) 0.134 0.50 (0.20, 1.24) 0.134 1.04 (0.33, 3.34) 0.944
MDRDGFR Q2 versus Q1 0.83 (0.35, 2.00) 0.679 0.89 (0.36, 2.18) 0.798   
MDRDGFR Q3 versus Q1 0.55 (0.23, 1.33) 0.184 0.58 (0.24, 1.40) 0.224   
MDRDGFR Q4 versus Q1 0.66 (0.26, 1.63) 0.361 0.70 (0.28, 1.78) 0.456   
BMI 1.03 (0.99, 1.07) 0.15 1.03 (0.99, 1.08) 0.112   
Hip circumference 1.05 (1.00, 1.11) 0.091 1.06 (1.00, 1.12) 0.056   
Systolic BP 1.01 (0.99, 1.03) 0.229 1.01 (0.99, 1.03) 0.216   
Diastolic BP 1.02 (0.99, 1.06) 0.158 1.03 (0.99, 1.06) 0.120   
LDL-C Q2 versus Q1 0.53 (0.22, 1.32) 0.174 0.55 (0.22, 1.42) 0.217   
LDL-C Q3 versus Q1 0.77 (0.31, 1.90) 0.565 0.76 (0.30, 1.90) 0.553   
LDL-C Q4 versus Q1 0.62 (0.25, 1.54) 0.305 0.66 (0.26, 1.73) 0.403   
Total volume Q2 versus Q1 1.82 (0.73, 4.55) 0.201 1.87 (0.73, 4.78) 0.190   
Total volume Q3 versus Q1 2.25 (0.91, 5.56) 0.079 2.22 (0.81, 6.06) 0.121   
Total volume Q4 versus Q1 0.96 (0.38, 2.45) 0.935 0.86 (0.26, 2.82) 0.804   
Statin use 1.43 (0.75, 2.75) 0.278 1.51 (0.76, 3.01) 0.239   
Smoking 1.46 (0.75, 2.85) 0.270 1.50 (0.75, 2.98) 0.249   
Waist-hip ratio 2.33 (0.03, 190) 0.707     
Hypertension 1.00 (0.52, 1.92) 1.00     
Diabetes 1.26 (0.65, 2.48) 0.495     
Lifetime ASCVD risk % 1.01 (0.98, 1.04) 0.726     
Creatinine 2.11 (0.40, 10.99) 0.376     
Oxidized LDL-C 1.00 (0.98, 1.30) 0.737     
Hematocrit 1.00 (0.92, 1.09) 0.932     
Ferritin 1.00 (0.99, 1.00) 0.955     
Hepcidin 1.00 (1.00, 1.02) 0.651     
Adiponectin 1.00 (0.99, 1.00) 0.485     
  1. HDL-C high-density lipoprotein cholesterol, MDRDGFR modification of diet in renal disease-derived glomerular filtration rate, BMI body mass index, BP blood pressure, LDL-C low-density lipoprotein cholesterol, ASCVD atherosclerotic cardiovascular disease